PubMed دسترسی آزاد

Proteome-wide curation of experimentally validated HPV T-cell epitopes identifies key gaps in our understanding of cellular immunity to HPV and informs vaccine design.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

BACKGROUND: Human papillomavirus (HPV) drives both malignant and benign tumours. Current prophylactic vaccines are type-restricted, not optimised for T-cell induction, and lack therapeutic efficacy. Although T-cells are critical for both preventing and clearing HPV infection, experimentally validated HPV T-cell epitopes remain fragmented across the literature, limiting systematic evaluation of cellular immune targets. METHODS: We curated experimentally validated HPV T-cell epitopes from the Immune Epitope Database (IEDB). Epitopes were mapped across HPV proteins and genotypes, and analysed for response rate, sequence conservation across 454 representative HPV genomes, and HLA restriction patterns. RESULTS: 485 unique experimentally validated HPV epitopes have been described (133 studies; 1,494 functional assays). Consistent with research focus and viral biology, E6 and E7 proteins account for >60% of known HPV epitopes despite accounting for ~10% of the viral proteome. High-risk HPV types, especially HPV16 and HPV18, were the most studied (p <.001) and were enriched for CD8+ epitopes (p <.001). We identified major knowledge gaps, including: underrepresentation of structural proteins such as L2; limited epitope coverage for low-prevalence HPV genotypes; a bias towards common HLA alleles. In silico analysis indicated greater conservation of epitopes in L1/L2 and across high-risk HPV types. Conserved, commonly detected, and HLA-promiscuous epitopes were highlighted and we provide panels of candidate epitopes for consideration in immune monitoring, broad-spectrum prophylactic vaccines, and high-risk targeted therapeutic vaccines. CONCLUSION: This study provides the first comprehensive atlas of experimentally validated HPV T-cell epitopes and ranked epitope candidates for translational application. We demonstrate that our understanding of HPV T-cell immunity is constrained by biases in antigen, genotype and HLA focus and by incomplete epitope mapping. Addressing these gaps will be essential for a comprehensive assessment of cellular immunity and for utilising T-cells in next-generation vaccines.

متن کامل اصلی

نسخه دارای مجوز در منبع علمی در دسترس است.

لینک مستقیم از metadata منبع گرفته شده و در تب جدید باز می‌شود.

باز کردن متن کامل

کلیدواژه‌ها

T-cell epitopeconservationcross-reactivityhuman papillomavirusvaccine design
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

Barry Bloom and the convergence of immunology, infectious disease, and public health.

In early 2026, the world lost Barry Bloom, a great advocate for public health, an extraordinarily accomplished immunologist, and a science advisor who helped refocus policy on controlling infectious diseases, including neglected diseases such as leprosy. Barry's career took him from a life of laboratory discovery where he was enormously influential in catalyzing the late 20th century shift from studying the immune response of simple mo…

PubMed2026

Trajectories in immunometabolism.

Immunometabolism has rapidly evolved from an emerging area within immunology into a topic that not only impregnates most aspects of immune research but also reveals itself as a defining feature of the immune response. At the European Immunometabolism Conference celebrated in June, we asked some of the speakers to share their personal journey as researchers in this field and what questions they are currently working on.

PubMed2026

Hazy mysteries and the major histocompatibility complex: a journey.

I was pleased to receive an invitation to write a historical perspective on my career. As I understand it, these perspectives aim to illustrate the often-twisted paths to discoveries, the fortuitous events that often enable them, and the pitfalls along the way. At the same time, they can be expected to illustrate the influence of the particular "tastes" and interests of a scientist in the choices that are made along the way and that th…